Search

Male and female CD-1 mice (50 mice per group) were administered thiabendazole (TBZ) in diet at levels of 0 (control), 0.031, 0.125 and 0.5% for 78 weeks. A life time study was terminated after 78 weeks due to enhanced strain specific mortality. There were no significant differences in mortality between the control and treated groups. Mean body weights of high-dose groups showed significant decreases compared with the controls. The bladder weights of male and female mice of the 0.5% group were significantly higher than those of the control mice. Gross findings in treated mice included the renal atrophy, hydronephrosis, calculi in renal pelvis and/or bladder and ovarian atrophy. Microscopic findings in the kidneys of treated mice included the nephrosis, hydronephrosis or hyperplasia of transitional epithelium of renal pelvis or papilla. In the bladder of treated mice, hyperplasia or squamous metaplasia of transitional epithelium and one transitional cell papilloma were observed. Dose-dependent decreases in the incidence of spontaneous lesion in the male or female reproductive system were recognized. It is concluded that TBZ is not carcinogenic to CD-1 mice of both sexes. However, caution should be exercised in the long-term application of high TBZ doses.

Male ICR mice were administered thiabendazole (TBZ) in the diet at concentration of 0 (control), 0.8, 1.2 and 1.6% for 44 weeks. The mortality was 10, 6, 40 or 90% in control, 0.8, 1.2 or 1.6% TBZ group, respectively. In dead mice, the gross findings included the abnormalities of kidney such as atrophy, hydronephrosis or swelling in 2, 67, 95 or 96% of the 0, 0.8, 1.2 or 1.6% TBZ group, respectively. In surviving mice at the end of study, the right kidney weight of treated groups was significantly lower than that of control group. The urinary bladder weight of treated groups was significantly higher than that of control group. Gross findings in treated mice included the renal atrophy, hydronephrosis, calculi in renal pelvis or urinary bladder and thickening of the bladder wall. Microscopic findings in the kidneys of treated mice included nephrosis, hydronephrosis and hyperplasia of transitional epithelium of renal pelvis and/or papilla. In the urinary bladder, hyperplasia or squamous metaplasia of transitional epithelium were found in treated mice. Administration of TBZ in the diet for 44 weeks results in nephrosis and calculus formation in the renal pelvis and urinary bladder of male ICR mice, and is associated with hyperplasia of transitional epithelium of renal pelvis or urinary bladder.

Male and female CD-1 mice (51–104 mice/group) were administered piperonyl butoxide (α-[2-(2-butoxyethoxy)ethoxy-4,5-methylenedioxy-2-propyltoluene) in the diet at levels of 0 (control), 0.6 and 1.2% for 52 weeks (1 year). Hepatocellular carcinomas were induced in treated groups in a dose-dependent manner. The incidences of hepatocellular carcinoma were 11.3 and 52.0% in male mice given 0.6 and 1.2% piperonyl butoxide, and 41.2% in female mice given 1.2%. Piperonyl butoxide is thus a hepatocarcinogen to mice as it is known to be to rats.

Chlorpropham[Isopropyl-N-(3-chlorophenyl)carbamate; CIPC] is a widely used sprout suppressant. Groups of ten male and ten female F344 rats were given 0, 7500, 15,000 or 30,000 ppm of CIPC in the diet for 13 weeks. Body weight gain of male and female rats in the 30,000 ppm-group was depressed. Spleen and liver weights of male and female rats in the treated groups were dose-dependently increased. Red blood cell count, hemoglobin concentration, hematocrit, mean corpuscular hemoglobin concentration and platelet count were decreased in male and female rats of the treated groups. Methemoglobin level, mean corpuscular volume and mean corpuscular hemoglobin were increased in male and female rats of the treated groups. Those hematological changes were dose-dependent and were marked in the 15,000 and 30,000 ppm-groups. White blood cell count of male and female rats in the 30,000 ppm-group were significantly higher than those of the control group. Congestion, increased hemosiderin deposition, increased extramedullary hemopoiesis, lymphoid atrophy and fibrosis were seen in spleen of male and female rats of all treated groups in a dose-dependent manner. Hemopoietic cell hyperplasia was marked in bone marrow of male and female rats in all treated groups. The results suggested that the erythrocyte is one of the primary targets of CIPC toxicity in rats.

The nephrotoxicity and recovery following administration of thiabendazole (TBZ) were investigated in ICR adult mice. A single oral administration of TBZ (500-2000 mg/kg body wt.) caused a dose-dependent proximal tubular necrosis in the kidney and increase in serum urea nitrogen 24 h after dosing. These changes were marked in mice of high dose groups (1000 or 2000 mg TBZ/kg body wt.). The time course of changes on kidney of mice treated with 1000 or 2000 mg TBZ/kg body weight were examined at 1, 2, 3, 5, 7 or 10 days after dosing. Light microscopy showed necrosis of proximal convoluted tubules from 1 day after dosing. Tubular necrosis was extensive 2 or 3 days after dosing. Partial regeneration from tubular necrosis was seen 3 days after dosing, and substantial regeneration had occurred from 5 days after dosing. Thus, TBZ-induced renal injury was most severe at 2 or 3 days after dosing and was followed by regeneration. Electron microscopy showed swelling of mitochondria in the proximal tubular epithelium at 1 day after dosing. The pathological changes were correlated with the changes in urinalysis, serum urea nitrogen concentration and kidney weight.

Male F344 rats were given 0, 0.6, 1.2 or 2.4% of piperonyl butoxide in the diet. at 1, 2, 4 or 12 weeks after the beginning of the experiment, liver and kidney weight and serum clinical parameters were determined and livers and kidneys were examined with light microscopy. From 1 or 2–12 weeks, distinct increase of liver weight, changes in serum clinical parameters for liver damage, oval cell proliferation, bile duct hyperplasia, single cell necrosis, enlarged and vacuolated hepatocytes, enlarged nuclei and anisonucleosis were seen in treated rats. From 4–12 weeks, cell infiltration, focal necrosis, multinucleated hepatocytes and prominent nucleoli of hepatocytes were seen in treated rats. At 12 weeks microgranulomas were seen in treated rats. Especially in rats of the 2.4% group at 12 weeks, severe enlargement of hepatocytes, severe enlargement of nuclei and multinucleated hepatocyte were seen, suggesting preneoplastic alteration. Relative kidney weights and serum urea nitrogen levels were increased in treated rats from 1 or 2–12 weeks and at 12 weeks, atrophy of proximal tubules, dilation of tubules, cell infiltration, fibrosis and accumulation of yellow-brown pigment in the proximal tubular cells were seen.

Piperonyl butoxide, alpha-[2-(2-Butoxyethoxy)ethoxy]-4,5-methylenedioxy-2-propyltoluene, is a pesticide synergist. F344 rats of both sex were maintained on diets containing 0, 0.6, 1.2 or 2.4% of piperonyl butoxide for 13 weeks. At the end of experimental period, they were necropsied. Selected organs were weighed and serum was analyzed by clinical chemistry. In male and female rats of the 2.4%-group, body weight gains were depressed, macroscopically, hepatomegaly was marked and liver weights were significantly higher than those of the control group. In male and female rats of all treated groups, relative kidney weights were significantly increased in a dose-dependent manner. Rats of the 2.4%-group had increased levels of albumin, cholesterol, urea nitrogen and gamma-glutamyl transpeptidase. Examination of livers of the male 2.4%-group by light microscopy showed enlarged hepatocytes with glassy cytoplasm and fatty deposition. On occasion, there was coagulative necrosis of a few hepatocytes in the periportal area and oval cell proliferation. The kidney of treated rats showed atrophy of epithelium in the proximal convoluted tubules. These results indicated that toxicity of piperonyl butoxide in rats was directed primarily to the liver and kidney.